AI Article Synopsis
- The systematic review focused on the antibacterial mechanisms and modes of action of trypsin inhibitors, with a protocol registered for proper tracking.
- A total of 2,382 articles were initially identified, but only 17 met the eligibility criteria after thorough screening based on specific selection criteria across multiple databases.
- Findings revealed that some studies highlighted the direct action of trypsin inhibitors on bacterial membranes and proteases, while others indicated their potential to create either bacteriostatic or bactericidal effects without detailing the underlying mechanisms.
Article Abstract
This systematic review (SR) aimed to gather studies describing the antibacterial action mechanisms and mode of trypsin inhibitors. The review protocol was registered (PROSPERO: CRD42020189069). Original articles resulting from studies in animal models, in bacterial culture, and using cells that describe antibacterial action of trypsin inhibitor-type peptides or proteins were selected in PubMed, Science Direct, Scopus, Web of Science, BVS, and EMBASE. The methodological quality assessment was performed using the PRISMA and OHAT tool. 2382 articles were retrieved, 17 of which were eligible. Four studies demonstrated the action mechanism directly on the bacterial membrane, and the fifth study on endogenous proteases extracted from the bacteria themselves. The antibacterial action mode was presented in the other studies, which can generate bacteriostatic or bactericidal effects without describing the mechanisms. This study generated information to enable new preclinical or clinical studies with molecules contributing to public health.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8856033 | PMC |
| http://dx.doi.org/10.1080/14756366.2022.2039918 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring the interactions of rapamycin with target receptors in A549 cancer cells: insights from molecular docking analysis.
J Cancer Res Clin Oncol
January 2025
School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India.
Rapamycin, a macrocyclic antibiotic derived from the actinomycetes Streptomyces hygroscopicus, is a widely used immunosuppressant and anticancer drug. Even though rapamycin is regarded as a multipotent drug acting against a broad array of anomalies and diseases, the mechanism of action of rapamycin and associated pathways have not been studied and reported clearly. Also reports on the binding of rapamycin to cancer cell receptors are limited to the serine/threonine protein kinase mTORC1.
View Article and Find Full Text PDFAuranofin induces disulfide bond-mimicking S-Au adducts in protein thiol pairs.
J Biol Chem
January 2025
Microbial Biochemistry, Faculty of Medicine, Ruhr University Bochum, 44780 Bochum, Germany. Electronic address:
Auranofin is an inhibitor of human thioredoxin reductase, clinically used in the treatment of rheumatoid arthritis. More recently, it has been shown to possess strong antibacterial activity. Despite the structural dissimilarity and the independent evolutionary origins of human thioredoxin reductase and its bacterial counterpart (TrxB), inhibition of bacterial thioredoxin reductase is often suggested to be a major factor in auranofin's antibacterial mode of action.
View Article and Find Full Text PDFStructure-Guided Development of ClpP Agonists with Potent Therapeutic Activities against Infection.
J Med Chem
January 2025
State Key Laboratory of Drug Research, Centre for Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Peritonitis caused by poses a severe threat to patients with end-stage renal failure. Treating multidrug-resistant infections requires the use of antibiotics with diverse mechanisms of action. Caseinolytic protease P (ClpP) is a promising antibacterial target; however, selective activation of (ClpP) over human ClpP (ClpP) remains challenging.
View Article and Find Full Text PDFImmunomodulatory peptides: new therapeutic horizons for emerging and re-emerging infectious diseases.
Front Microbiol
December 2024
School of Biosciences and Technology, Vellore Institute of Technology SBST, Vellore, Tamil Nadu, India.
The emergence and re-emergence of multi-drug-resistant (MDR) infectious diseases have once again posed a significant global health challenge, largely attributed to the development of bacterial resistance to conventional anti-microbial treatments. To mitigate the risk of drug resistance globally, both antibiotics and immunotherapy are essential. Antimicrobial peptides (AMPs), also referred to as host defense peptides (HDPs), present a promising therapeutic alternative for treating drug-resistant infections due to their various mechanisms of action, which encompass antimicrobial and immunomodulatory effects.
View Article and Find Full Text PDFAmniotic membrane, a novel bioscaffold in cardiac diseases: from mechanism to applications.
Front Bioeng Biotechnol
December 2024
Department of Biomedical Engineering, Meybod University, Meybod, Iran.
Cardiovascular diseases represent one of the leading causes of death worldwide. Despite significant advances in the diagnosis and treatment of these diseases, numerous challenges remain in managing them. One of these challenges is the need for replacements for damaged cardiac tissues that can restore the normal function of the heart.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!